Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?

Simply Wall St.02-24

If you are wondering whether Teva Pharmaceutical Industries is still good value after its recent run, this article walks through what the current share price might be implying about the company. Teva'...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2613571632?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850","is_english":true,"pubTime":"2026-02-24 19:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2613571632","market":"sg","top_or_hot":-1,"title":"Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether Teva Pharmaceutical Industries is still good value after its recent run, this article walks through what the current share price might be implying about the company. Teva'...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/has-teva-teva-run-too-far-after-its-102-one-year-share-price\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Has Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHas Teva (TEVA) Run Too Far After Its 102% One-Year Share Price Surge?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-24 19:22 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/has-teva-teva-run-too-far-after-its-102-one-year-share-price><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether Teva Pharmaceutical Industries is still good value after its recent run, this article walks through what the current share price might be implying about the company. Teva'...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/has-teva-teva-run-too-far-after-its-102-one-year-share-price\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4557","symbol_name":"大麻股","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/has-teva-teva-run-too-far-after-its-102-one-year-share-price","article_id":"2613571632","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/308047-main-header/1585187365850"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-teva/teva-pharmaceutical-industries/news/has-teva-teva-run-too-far-after-its-102-one-year-share-price","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2613571632","pubTimestamp":1771932123,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether Teva Pharmaceutical Industries is still good value after its recent run, this article walks through what the current share price might be implying about the company.\nTeva's share price last closed at US$33.91, with returns of 6.6% over the past 30 days, 9.6% year to date and 102.1% over the last year. The 3 year and 5 year returns sit at 242.5% and 210.5% respectively, which raises the question of how much optimism is already reflected in the price.\nRecent...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4557":"大麻股","BK4588":"碎股","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","BK4007":"制药","BK4596":"哈里斯概念","BK4559":"巴菲特持仓","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","BK4584":"避孕概念","BK4566":"资本集团","LU1983299246.USD":"SCHRODER ISF HEALTHCARE INNOVATION \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","TEVA":"梯瓦制药"},"translate_title":"梯瓦(TEVA)股价一年飙升102%后是否走得太远了？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEVA":1.5,"DCF":1},"content_text":"If you are wondering whether Teva Pharmaceutical Industries is still good value after its recent run, this article walks through what the current share price might be implying about the company. Teva's share price last closed at US$33.91, with returns of 6.6% over the past 30 days, 9.6% year to date and 102.1% over the last year. The 3 year and 5 year returns sit at 242.5% and 210.5% respectively, which raises the question of how much optimism is already reflected in the price. Recent coverage around Teva has focused on its position in the global generics and specialty pharmaceuticals space and investor attention on how it is managing its business mix and balance sheet. This backdrop helps explain why the market has been reassessing the stock and why sentiment has shifted over the past few years. On our simple valuation framework, Teva scores 2 out of 6 on undervaluation checks. Next we will look at how different valuation approaches stack up for the stock and then finish with a way to think about value that goes beyond the usual ratios.  Teva Pharmaceutical Industries scores just 2/6 on our valuation checks. See what other red flags we found in the full valuation breakdown. AdvertisementApproach 1: Teva Pharmaceutical Industries Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow model takes estimates of the cash a company may generate in the future and discounts those projections back to what they could be worth in today’s dollars. It is essentially asking what a stream of future cash flows might be worth right now. For Teva Pharmaceutical Industries, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $1.12b. Analyst and extrapolated projections suggest free cash flow reaching around $4.12b by 2030, with a series of annual forecasts between 2026 and 2035 that are discounted back to today using Simply Wall St’s assumptions. On this basis, the estimated intrinsic value comes out at about $59.02 per share. Compared with the recent share price of $33.91, the DCF output points to an implied discount of roughly 42.5%, which indicates the stock currently screens as undervalued on this model alone. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Teva Pharmaceutical Industries is undervalued by 42.5%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks. TEVA Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Teva Pharmaceutical Industries. Approach 2: Teva Pharmaceutical Industries Price vs Earnings For a profitable business like Teva Pharmaceutical Industries, the P/E ratio is a useful way to think about what you are paying for each dollar of earnings. It gives a quick sense of how the market is weighing the company’s profit outlook against the risks around it. What counts as a “normal” P/E ratio typically reflects two things: how fast earnings are expected to grow and how risky those earnings are perceived to be. Higher growth or lower perceived risk often goes with a higher P/E, while slower growth or higher risk usually lines up with a lower P/E. Teva currently trades on a P/E of 28.0x. That sits above the Pharmaceuticals industry average of 19.9x and also above the peer group average of 20.7x. Simply Wall St’s Fair Ratio for Teva is 25.6x, which is its proprietary view of what the P/E “should” be given factors like earnings growth, profit margins, industry, market cap and risk profile. Because this Fair Ratio is tailored to Teva’s own characteristics, it can provide a more company specific anchor than a simple comparison with peers or the broader industry. On this basis, the current P/E is higher than the Fair Ratio, which points to the shares screening as overvalued on this metric. Result: OVERVALUED NYSE:TEVA P/E Ratio as at Feb 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Teva Pharmaceutical Industries Narrative Earlier we mentioned that there is an even better way to understand valuation. Let us introduce you to Narratives, which are simply your story about Teva Pharmaceutical Industries, linked to your own revenue, earnings and margin expectations. These expectations are turned into a fair value that you can compare with the current price, all inside Simply Wall St’s Community page where millions of investors share views that update as fresh news or earnings arrive. For Teva, you might see one Narrative that aligns with a higher fair value around US$37.95 and another that is closer to the lower US$21.53 end of the range. By choosing the story you find most reasonable, you are effectively choosing the fair value anchor that guides whether the current price looks attractive or not. For Teva Pharmaceutical Industries, here are previews of two leading Teva Pharmaceutical Industries Narratives to make comparison easier for you: Together, they bracket a reasonable range of outcomes so you can decide which set of assumptions feels closer to your own view before you look at the current share price. 🐂 Teva Pharmaceutical Industries Bull Case Fair value in this bull case narrative: US$37.95 per share. At the recent price of US$33.91, that implies Teva trades at about 10.7% below this fair value anchor. Revenue growth assumption used in this narrative: 132.41%.  Analysts in this camp see Teva’s mix of branded drugs, biosimilars and a broad generics base as supporting steady, higher margin growth if R&D progress and product launches track to plan. They factor in cost savings, modernization and a stable generics platform as important supports for free cash flow and ongoing debt reduction, while still acknowledging debt and regulatory risks. The updated fair value reflects slightly adjusted discount rates, higher revenue growth inputs and expectations around 2026 pipeline catalysts and the “affordable medicines” theme.  🐻 Teva Pharmaceutical Industries Bear Case Fair value in this bear case narrative: US$21.53 per share. At the recent price of US$33.91, that implies Teva trades at about 57.6% above this fair value anchor. Revenue growth assumption used in this narrative: 1.01%.  This view leans on a lower price target and assumes only modest revenue growth, with questions over how much Teva can rely on a handful of branded products and late stage pipeline assets without setbacks. It highlights risks around competitive pressure in generics and biosimilars, execution and regulatory risk in the pipeline, cost savings that may be harder to capture, and uncertainty around supply chain and asset sales. Even though earnings and margins are expected to improve in this scenario, the concern is that current market expectations sit too high relative to these more cautious assumptions.  If you want to see how other investors are weighing these stories against the current price, you can use the Community Narratives as a starting point and then adjust the numbers to fit your own expectations for Teva’s revenues, margins and balance sheet over the next few years. Curious how numbers become stories that shape markets? Explore Community Narratives Do you think there's more to the story for Teva Pharmaceutical Industries? Head over to our Community to see what others are saying! NYSE:TEVA 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Teva Pharmaceutical Industries might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2613571632","isCrawlerRequest":true}